 |
20 Diseases |  |
18 Trials |
|
18 Trials |  |
1690 News |  |
| «12345678910111213...1920» |
- Lorbrena (lorlatinib) / Pfizer, NVL-655 / Nuvalent
Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_354;
NVL-655 showed activity in diverse patient-derived models of ALK-positive cancers, including ones that exhibited clinical resistance to prior-generation ALK TKIs. The broad preclinical activity of NVL-655 suggests potential utility as a best-in-class therapy for ALK-positive cancer patients.
- | Zykadia (ceritinib) / Novartis
Journal: Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report. (Pubmed Central) - Sep 2, 2022
Whether this finding represents an inherent property of this fusion protein or its unique clinicopathological characteristics in patients carrying this fusion protein remains to be investigated. Moreover, the patient's durable response to ceritinib and future resistance mechanisms require further follow-up.
- A Bayesian Network Meta-Analysis of the Tyrosine Kinase Inhibitors (TKI) for ALK-Positive Advanced Non-Small Cell Lung Cancer With or Without Brain Metastasis (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2577;
Moreover, the patient's durable response to ceritinib and future resistance mechanisms require further follow-up. Lorlatinib showed better estimates of efficacy in comparison to the first and second generation TKIs especially in PFS, with its ranking by the front, which can be considered as the best option for clinical treatment.
- Understanding Treatment Patterns, Disruptions and Potential Limitations of Tyrosine Kinase Inhibitors in ROS1+ Non-Small Cell Lung Cancer Patients in a Retrospective Review of United States Medical Transcription Records (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1955;
Time on TKI therapy varied considerably with majority of patients experiencing early treatment disruptions. Results suggest possible unmet need among ROS1+ NSCLC patients using contemporary TKIs since treatment disruptions can occur within 3 months of initiation, use may be sporadic, and many patients experience disease progression and tolerability issues.
- Healthcare Resource Utilization (HCRU) of United States ROS1+ Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Tyrosine Kinase Inhibitors (TKIs): Analysis of Electronic Medical Transcription Records (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1652;
Most common major events were referrals to specialist, unscheduled visit to ER/clinic, and admittance to hospital. As ROS1+ NSCLC patients are routinely managed, unexpected HCRU events from their current TKIs may be common, and add to the overall economic burden of this condition.
- || Clinical, Retrospective data, Journal: Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. (Pubmed Central) - Aug 30, 2022
Lorlatinib may have advantageous PFS compared with other agents but a greater risk of severe toxicity. Second-generation inhibitors, including alectinib, brigatinib, and ensartinib, provide major efficacy with less toxicity and remain appropriate regimens in the front-line setting.
- | Zykadia (ceritinib) / Novartis
Journal, IO biomarker: Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy. (Pubmed Central) - Aug 28, 2022
Ceritinib is a novel CD39 inhibitor with high metabolic stability and optimized physicochemical properties; according to our knowledge, it is the first brain-permeant CD39 inhibitor. Our discovery will provide the basis (i) to develop more potent and balanced dual CD39/ALK inhibitors, and (ii) to optimize the ceritinib scaffold towards interaction with CD39 to obtain potent and selective drug-like CD39 inhibitors for future in vivo studies.
- | Zykadia (ceritinib) / Novartis
Journal: Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma. (Pubmed Central) - Aug 26, 2022
However, biopsies of the pulmonary nodules revealed features of granulomatous inflammation without definite cancer cells. We documented for the first time that ceritinib might be associated with pulmonary granulomatous inflammation, and clinicians should be alert to the possibility that the rare adverse event emerged during ceritinib treatment.
- |||| Zykadia (ceritinib) / Novartis
Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy | Journal for ImmunoTherapy of Cancer https://t.co/9RA5UBLzl1 (Twitter) - Aug 26, 2022
- || Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
P4 data, Review, Journal: Photosensitivity associated with anaplastic lymphoma kinase inhibitors: a review of postmarketing cases reported to FDA and published in the literature. (Pubmed Central) - Aug 24, 2022
We documented for the first time that ceritinib might be associated with pulmonary granulomatous inflammation, and clinicians should be alert to the possibility that the rare adverse event emerged during ceritinib treatment. No abstract available
- The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis (Zone 2, Science and Technology Hall, Level 3; Poster Board no. 2057) - Aug 20, 2022 - Abstract #AHA2022AHA_5945;
However, the cardiovascular safety profile of these agents remains understudied. We interrogated the Food and Drug Administration
- ||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Clinical, P1/2 data: Wow!!! This is the reaction we had ten years ago to the Phase I/II initial ceritinib post-crizotinib trial. Doesn’t happen that often. Well done!! More good for patients. (Twitter) - Aug 13, 2022
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Biomarker, Journal, Next-generation sequencing: Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. (Pubmed Central) - Aug 12, 2022
We interrogated the Food and Drug Administration cfDNA-NGS facilitates detection of ALK fusions and resistance mutations, assessment of prognosis, and monitoring dynamic changes of genomic alterations in ALK+ NSCLC treated with ALK-TKI.
- | Zykadia (ceritinib) / Novartis
Journal: 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. (Pubmed Central) - Aug 6, 2022
Taken together, our findings indicate that ZX-42 shows more effective activity than ceritinib against ALK-positive ALCL. We hope this study can provide a direction for the structural modification of ceritinib and lay the foundation for the further development of clinical research in ALK-positive ALCL.
- | Danyelza (naxitamab) - Y / mAbs Therap
New P2 trial: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Aug 5, 2022
P2, N=76, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
- || Review, Journal: A Comprehensive Review of the Pharmacologic Perspective on Loop Diuretic Drug Interactions with Therapeutically Used Drugs. (Pubmed Central) - Jul 30, 2022
Clinicians, pharmacists and other health care providers should take responsibility for the safe use of medications. In addition, they are required to be aware of the drugs interacting with loop diuretics to prevent adverse drug interactions.
- || Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Review, Journal: Anaplastic lymphoma kinase inhibitors and their effect on the kidney. (Pubmed Central) - Jul 29, 2022
According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.
- || Retrospective data, Review, Journal: Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. (Pubmed Central) - Jul 23, 2022
Lorlatinib had a high incidence of hypertriglyceridemia and hypercholesterolemia, which were rarely reported in other ALK inhibitors. The incidences of grade ≥ 3 AEs for individual ALK inhibitor were moderately high yet manageable. Different toxicity spectrums were found in each ALK inhibitor.
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Gilotrif (afatinib) / Boehringer Ingelheim
New trial: Antineoplastic Drugs in Elderly Patients (clinicaltrials.gov) - Jul 20, 2022
P=N/A, N=500, Recruiting, Sponsor: Shandong University
- | Lorbrena (lorlatinib) / Pfizer, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker: Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. (Pubmed Central) - Jul 17, 2022
She was treated with alectinib and acquired ALK p.I1171N and p.V1180L mutations...After sequential lines of ceritinib and chemotherapy, lorlatinib was chosen as the fourth-line therapy and maintained control for 6 months...To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK-positive, gBRCA-mutated metastatic NSCLC. Together with previous reports in EGFR-positive or driver-negative patients, our finding warrants further studies on PARP inhibition in BRCA1/2-mutated NSCLC.
- Zykadia (ceritinib) / Novartis, alvocidib (DSP-2033) / Sumitomo Dainippon, dinaciclib (MK-7965) / Ligand, Merck (MSD)
IDENTIFICATION OF NOVEL THERAPEUTICS FOR HEPATOBLASTOMA USING A PATIENT-DERIVED XENOGRAFT IN VITRO DRUG TESTING PLATFORM (Hall 7) - Jul 16, 2022 - Abstract #SIOP2022SIOP_480;
Most importantly, these drugs significantly reduced growth of a patient-derived xenograft model when transplanted into nude mice.ConclusionsWe were able to establish a platform for rapid, reproducible and reliable validation of potential drug candidates. Our results strongly suggest that ceritinib, dinaciclib, alvocidib, and mebendazole can be applied as an alternative therapeutic approach for hepatoblastoma.
- |||| Zykadia (ceritinib) / Novartis
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @myESMO @ESMO_Open https://t.co/fMCw3bhfta (Twitter) - Jul 10, 2022
- ||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer @notahedge @JCOPO_ASCO https://t.co/h4q4WS8iZj (Twitter) - Jul 2, 2022
- | Zykadia (ceritinib) / Novartis
Journal: Ceritinib is a novel triple negative breast cancer therapeutic agent. (Pubmed Central) - Jul 1, 2022
Furthermore, we introduced a novel therapeutic combination of ceritinib and paclitaxel for AR negative or AR-low TNBCs and this combination inhibited tumor growth to a great extent. All agents used in our study are FDA-approved, and thus the proposed combination therapy will likely be useful in the clinic.
- || Zykadia (ceritinib) / Novartis
Trial completion date, Trial primary completion date: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 1, 2022
P1, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
All agents used in our study are FDA-approved, and thus the proposed combination therapy will likely be useful in the clinic. Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- | Zykadia (ceritinib) / Novartis
Biomarker, Enrollment closed, Enrollment change, Combination therapy, Metastases: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 30, 2022
P1, N=37, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023 Recruiting --> Active, not recruiting | N=66 --> 37
- || Zykadia (ceritinib) / Novartis
Trial completion date, Trial primary completion date: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 30, 2022
P1, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=66 --> 37 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- ||| Zykadia (ceritinib) / Novartis
Ceritinib is a novel triple negative breast cancer therapeutic agent | Molecular Cancer | Full Text @SheldonLHolder @DrSGraff @bcarneiro7 @drdonsdizon https://t.co/5wpgLTcEBv (Twitter) - Jun 29, 2022
- Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Clinicopathological Features of ROS1-rearranged Adenocarcinomas: A Single Institutional Experience Spanning Four Years From India (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1677;
Female gender preponderance, younger age at presentation and frequent bony metastases including an unusual presentation as a thyroid mass with occult lung primary were observed. Prospective screening with immunohistochemistry followed by confirmation with FISH is easily implementable to identify ROS1 rearranged adenocarcinomas in routine practice.
- Ensacove (ensartinib) / Xcovery
Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1115;
We firstly report that one patient with CNS metastases and a novel NBAS-ALK, EML4-ALK double-ALK fusion is sensitive to ensartinib. NSCLC patients with double-ALK fusion may benefit from ensartinib and the NGS could help predict the sensitivity and efficacy of ALK-TKIs.
- Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1109;
In our stage IV NSCLC population, there was no significant safety signal with sequential treatment of ICI followed by TKI; only one patient required treatment break/discontinuation due to pneumonitis. This differs from existing literature possibly because the majority of our population did not harbour a driver mutation and there were limited patients treated with crizotinib, ceritinib and osimertinib, other agents that have been associated with this safety signal.
- Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1093;
Comorbidity is associated with increased risk of treatment discontinuation among patients receiving current first-line next generation ALK TKIs (majority alectinib). The effectiveness of additional novel therapies for 1L treatment will be evaluated in future studies.Figure.
- Lorbrena (lorlatinib) / Pfizer, NVL-655 / Nuvalent
Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1002;
The potent preclinical activity of NVL-655 suggests potential clinical utility for ALK-positive patients, including those with resistant compound mutations. The MR448re PDC and xenograft are valuable additions to the ALK therapeutic research landscape where there is limited availability of patient-derived models with lorlatinib-resistant ALK compound mutations.
- Lorbrena (lorlatinib) / Pfizer
Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_989;
With median follow-up of 7.3 months, lorlatinib median time-to-discontinuation has not been reached. The interim findings indicate QoL was maintained among patients receiving lorlatinib.
- Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies (Hall C7) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_743;
P2
Brigatinib treatment demonstrated clinically meaningful efficacy in this integrated analysis of patients with advanced or metastatic ALK+ NSCLC who progressed on prior alectinib in the ALTA-2 or J-ALTA trials. Safety results were consistent with the known profile for brigatinib, with no new safety findings observed.
- Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC) (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_544;
Setting thresholds and negotiate drug prices should be prioritized to improve patients access to innovative This review showed how the cost-effectiveness thresholds varied among countries and provided an overview of the available cost-effectiveness findings for stakeholders. Setting thresholds and negotiate drug prices should be prioritized to improve patients access to innovative drugs, as iALK, in timely manner.
- ||| Zykadia (ceritinib) / Novartis
Trial completion date: ASCEND-4: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 22, 2022
P3, N=376, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Setting thresholds and negotiate drug prices should be prioritized to improve patients access to innovative drugs, as iALK, in timely manner. Trial completion date: Dec 2023 --> Apr 2024
- |||| Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Clinical, Real-world evidence: We also recently added another layer 👉🏼 added trial data + real world data 👉🏼Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/gffGjAk5ed via @JAMANetworkOpen part of @JAMANetwork (Twitter) - Jun 19, 2022
- | Lorbrena (lorlatinib) / Pfizer, Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis
Journal: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. (Pubmed Central) - Jun 19, 2022
Trial completion date: Dec 2023 --> Apr 2024 Our results provide a clinically relevant mechanistic model of ALKi resistance in neuroblastoma and highlight new clinically actionable collateral sensitivities in resistant cells.
- | Zykadia (ceritinib) / Novartis
Journal: ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. (Pubmed Central) - Jun 15, 2022
P2
Our results provide a clinically relevant mechanistic model of ALKi resistance in neuroblastoma and highlight new clinically actionable collateral sensitivities in resistant cells. Ceritinib showed antitumor activity in patients with ALK+ NSCLC with active brain metastases and/or leptomeningeal disease, and could be considered in the management of intracranial disease.
- | Zykadia (ceritinib) / Novartis
Journal: An ascendant challenge: central nervous system metastases in ALK+ lung cancers. (Pubmed Central) - Jun 15, 2022
Central nervous system (CNS) metastases constitute a challenge for the design of ALK fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate.
- || Zykadia (ceritinib) / Novartis
Clinical data, Retrospective data, Journal, Real-world evidence: Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China. (Pubmed Central) - Jun 11, 2022
Ceritinib administered at 450 mg QD to ALK-rearrangement NSCLC patients with BM in China exhibited superior ORR and DCR, as well as PFS and event free probability. The estimated 12-month EFP for intracranial lesions improved in patients with prior brain radiotherapy.
- || Alunbrig (brigatinib) / Takeda
Review, Journal: Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. (Pubmed Central) - Jun 11, 2022
The incidence of grade ≥3 AEs was similar between brigatinib and other next-generation ALK inhibitors (except for alectinib), while brigatinib could significantly delay the time to worsening in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status (GHS)/quality of life (QoL) vs. crizotinib (HR: 0.69, 95% CI: 0.49, 0.98). (4) Brigatinib had longer PFS compared to crizotinib and ceritinib and had comparable efficacy and safety profile with other 2nd-generation ALK inhibitors in first-line treatments for patients with ALK-positive non-small-cell lung cancer.
- || Retrospective data, Review: Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. (Pubmed Central) - Jun 4, 2022
Moreover, lorlatinib in never-smokers and low-dose alectinib in smokers could be considered optimal first-line therapy for advanced ALK-positive NSCLC. Acceptable limitations of evidence, such as study risk of bias, inconsistency, and imprecision, were present in this NMA.
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal, HEOR, Real-world evidence: Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence. (Pubmed Central) - May 29, 2022
Acceptable limitations of evidence, such as study risk of bias, inconsistency, and imprecision, were present in this NMA. Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure.
- ||||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Rozlytrek (entrectinib) / Roche
Clinical, IO biomarker: I would recommend mutation testing, at least EGFR/ALK, before giving neoadjuvant immunotherapy. I would also not recommend off label ceritinib for ROS1 NSCLC when crizotinib and entrectinib are approved and available. (Twitter) - May 27, 2022
- | Alunbrig (brigatinib) / Takeda
Journal: Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. (Pubmed Central) - May 24, 2022
Through a spurious exercise of an indirect comparison with other available 2G ALKi, we tent to summarize the required knowledge to properly choose the best drug at the right time. Furthermore, we reviewed available data on molecular resistance mechanisms and putative therapeutic applications in other contexts, such as ROS1+ NSCLC patients or EGFR+ ones progressing to osimertinib.
- ||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell Lung Cancer @JCOPO_ASCO https://t.co/W8fQa0GvET (Twitter) - May 12, 2022
- || Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Review, Journal, IO biomarker: Role of STK11 in ALK-positive non-small cell lung cancer. (Pubmed Central) - May 10, 2022
Therefore, the main purpose of this review was to summarize the role of STK11 in ALK-positive NSCLC. The present review also summarizes the treatment and drug resistance studies in ALK-positive NSCLC and the current status of STK11 research in NSCLC.
- Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
Trial completion date, Trial termination, Trial primary completion date, Metastases: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 10, 2022
P1/2, N=9, Terminated, Sponsor: University of California, San Francisco
The present review also summarizes the treatment and drug resistance studies in ALK-positive NSCLC and the current status of STK11 research in NSCLC. Trial completion date: Jan 2023 --> Apr 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Apr 2022; Low Accrual